Dihydrolipoic Acid (DHLA): A Comprehensive Reference
1. Identity: Chemical Names, Structure, and Natural Sources
1.1 Chemical Identity and Nomenclature
Dihydrolipoic acid (DHLA) is the reduced form of α-lipoic acid (LA). Its molecular formula is C₈H₁₆O₂S₂ (PubChem Compound ID: 421). DHLA carries several synonyms in the scientific literature, including dihydrothioctic acid, 6,8-dimercaptooctanoic acid, and reduced lipoic acid. Alpha-lipoic acid (ALA) is an eight-carbon structure that contains a disulfide bond as part of a dithiolane ring; other names for lipoic acid include thioctic acid, 6,8-thioctic acid, 6,8-dithioctane acid, and 1,2-dithiol-3-valeric acid.
Lipoic acid contains two sulfur atoms connected by a disulfide bond in the 1,2-dithiolane ring and carries a carboxylic acid group. It is considered to be oxidized relative to its acyclic relative dihydrolipoic acid, in which each sulfur exists as a thiol. In other words, when the disulfide ring of LA is reduced (opened), the two neighboring sulfur atoms each gain a hydrogen, producing two free sulfhydryl (–SH) groups and yielding DHLA.
The redox couple created by α-lipoic acid and dihydrolipoic acid is very potent, having a redox potential of −0.32 V, making it among the most powerful natural antioxidant couples. This couple is a better antioxidant agent than similar biological sulfur-containing redox pairs such as cystine/cysteine and glutathione and its oxidized state (GSH/GSSG), which have redox potentials of −0.24 V and −0.22 V.
As a sulfur-containing substance, ALA is considered a thiol compound. It exists as two enantiomers: (R)-(+)-lipoic acid (R-ALA) and (S)-(−)-lipoic acid (S-ALA), and as a racemic mixture. Only the R-(+)-enantiomer is synthesized in small amounts by microorganisms, plants, animals, and humans, and it is biologically active.
1.2 Natural Sources and Biosynthesis
Dihydrolipoic acid is a compound that occurs in the human organism and is in physiological equilibrium with alpha-lipoic acid; physiologically speaking, dihydrolipoic acid is the redox partner of alpha-lipoic acid.
ALA (the oxidized precursor to DHLA) is commonly found in dietary components such as vegetables (spinach, broccoli, tomato) and meats, mainly viscera. ALA can also be synthesized through enzymatic reactions in plants and animals' mitochondria from octanoic acid and cysteine (as a sulfur donor).
ALA is typically found in muscle meat, heart, kidney and liver, with lower amounts in fruits and vegetables. In general, it is not likely that the average Western diet contains appreciable quantities of ALA. Accordingly, dietary sources of free DHLA as such are negligible; DHLA exists endogenously as the product of enzymatic reduction of ALA within cells.
In human cells, LA is converted to dihydrolipoic acid (DHLA) by reduction of the dithiol group. LA is reduced by an NADH-dependent reaction with lipoamide dehydrogenase to form DHLA within the mitochondria. In most cells containing mitochondria, ALA is reduced by an NADH-dependent reaction with lipoamide dehydrogenase to form DHLA. In cells that lack mitochondria, ALA can be reduced to DHLA via NADPH with glutathione and thioredoxin reductases.
Normally, DHLA is formed in the cells. Cells tend to absorb ALA, reduce it to DHLA, and then secrete the DHLA into the bloodstream. Once in the bloodstream, DHLA can react with an oxidizing agent such as oxidized vitamin C, thereby scavenging oxygen from and regenerating the vitamin C, and forming ALA that can be reabsorbed by the cells. However, cells generally only produce an amount of DHLA sufficient for metabolic function. Additional or supplemental amounts of lipoic acid or DHLA must generally be derived from external sources such as dietary intake and/or nutritional supplements.
1.3 Common Forms and Preparations
Until recently, naturally occurring DHLA could only be obtained indirectly through consuming ALA, which in turn was converted by the body into small amounts of DHLA. However, this process does not deliver a significant or reliable supply of DHLA. Thus, ALA and DHLA for use in dietary supplements and medicaments have typically been derived from synthetic sources.
Commercially available alpha-lipoic acid (racemic alpha-lipoic acid) is a synthetic product consisting of two forms, the R+ and S− optical isomers in equal amounts. The R+ isomer is the naturally occurring lipoic acid. This isomer (R+) is the type the body makes and requires for its efficacy. DHLA itself is chemically unstable in open-air environments due to the reactivity of its free thiol groups, which are prone to oxidation. Chemical synthesis of dihydrolipoic acid has been established for a relatively long time and can in principle be realized by different reaction routes. In practice, dietary supplement formulations containing DHLA typically employ stabilizing agents or encapsulation technologies to prevent premature oxidation, and it is often administered in research settings as its sodium or other salt forms. Oral supplements and topical preparations containing ALA—which is then reduced to DHLA in vivo—are more common in the market than direct DHLA supplements.
2. Historical and Traditional Context
2.1 Discovery and Early Scientific History
DHLA does not itself have a traditional ethnobotanical or cultural history of use independent of its parent molecule. Rather, its history is inseparable from the biochemical discovery of alpha-lipoic acid. Alpha-lipoic acid (LA; 5-(1,2-dithiolan-3-yl)pentanoic acid) was originally isolated from bovine liver by Reed et al. in 1951. LA was once considered a vitamin; subsequently, it was found that LA is not a vitamin and is synthesized by plants and animals.
In the 1930s, it was found that a certain potato growth factor was necessary for growth of some bacteria. In 1951, a fat-soluble coenzyme factor was discovered from lactic acid bacteria. ALA was first isolated as an amphipathic molecule from liver tissue in 1951 by Reed et al. and was originally identified as an enzymatic cofactor of dihydrolipoate acyltransferase in the mitochondrial tricarboxylic acid cycle.
ALA was isolated by Reed in 1951 as an acetate-replacing factor, and its first clinical use dates from 1959 in the treatment of acute poisoning by Amanita phalloides, also known as the death cap mushroom. The recognition of DHLA as a distinct, biochemically active molecular species came with subsequent research into the redox cycling of lipoic acid, most prominently through the work of Lester Packer and colleagues at the University of California, Berkeley, in the late 1980s and 1990s.
Due to the discovery of new properties of this natural redox pair, the two natural substances have again increasingly attracted the interest of biology, biochemistry, medicine, nutritional science and technology.
2.2 Traditional Use of Dietary Sources
Because DHLA is not itself present in foods in substantial amounts (existing only transiently as a metabolic intermediate), there is no verifiable tradition of the direct use of DHLA as such by any historical culture. However, lipoic acid's role as a growth factor for microorganisms and as a cofactor for biochemical reactions in all organisms is well established. The cofactor was discovered originally in the conversion of pyruvate to acetate and as a factor essential for the oxidation of pyruvate. Foods rich in its precursor—particularly organ meats such as liver, heart, and kidney, and leafy vegetables such as spinach—were broadly esteemed in diverse traditional medical systems for their tonic and restorative properties, though this was understood in terms of their general nutritional content rather than any specific awareness of the LA/DHLA system.
In clinical and pharmaceutical history, lipoic acid (thioctic acid) has been used as a prescription medication in Germany and other European countries since the 1960s for the treatment of diabetic neuropathy, and this pharmaceutical tradition constitutes the closest approximation to a documented "traditional" therapeutic context for the LA/DHLA system.
3. Key Constituents and Established Mechanisms of Action
3.1 Structural Basis for Biological Activity
Dihydrolipoic acid (DHLA) is a constituent of cellular energy metabolism, where it cycles between the oxidized and reduced form. The two thiol residues of DHLA make this biomolecule susceptible to most radical species and prevent Fenton-type reactions by chelating free iron.
α-Lipoic acid (LA) is a low molecular weight dithiol antioxidant and is an important cofactor in several multienzyme complexes in the mitochondria. LA, and its reduced form dihydrolipoic acid (DHLA), has two free sulfhydryl groups, and the two forms LA/DHLA possess a high antioxidant potential capable of quenching reactive oxygen and nitrogen species such as hydroxyl radicals, peroxyl radicals, superoxide, and hypochlorous acid.
3.2 Direct Free Radical Scavenging
Dihydrolipoic acid (but not thioctic acid) was an efficient direct scavenger of peroxyl radicals generated in the aqueous phase and in liposomes or in microsomal membranes. Furthermore, dihydrolipoic acid (but not thioctic acid) reduced ascorbyl radicals (and dehydroascorbate) generated in the course of ascorbate oxidation by chromanoxyl radicals.
Lipoic acid is capable of scavenging only very reactive radicals, while the dehydrogenated (reduced) form, DHLA, is an excellent scavenger via a hydrogen transfer mechanism. The environment plays an important role in the free radical scavenging activity of DHLA because in water it is deprotonated, and this enhances its activity. In particular, the reaction rate constant of DHLA in water with an HOO• radical is close to the diffusion limit.
Research has established that the scavenging activity of dihydrolipoic acid toward hydroxyl radicals is not due to its chelating activity toward transition metals (ferrous ions), but rather dihydrolipoic acid is an efficient hydroxyl radical scavenger through a direct reaction mechanism.
DHLA is the predominant form that interacts with reactive oxygen species (ROS), but the oxidized form of LA can also inactivate free radicals.
3.3 Regeneration of Endogenous Antioxidants
One of DHLA's most significant and distinctive biological roles is its ability to restore other endogenous antioxidants that have been oxidized in the process of scavenging free radicals. Dihydrolipoic acid (DHLA), the reduced form of lipoic acid, restores these antioxidants by reducing their oxidized forms, maintaining redox balance through antioxidant regeneration.
DHLA, as the reduced form of ALA, mitigates oxidative damage by regenerating endogenous antioxidants, including vitamin E, vitamin C, and glutathione (GSH). Moreover, the DHLA-mediated reduction of the oxidized form of coenzyme Q10 contributes to the reduction of α-tocopherol free radical generation.
DHLA was found to exert antioxidant function in combination with coenzyme Q (ubiquinone). DHLA was found to reduce ubiquinone to ubiquinol by the transfer of a pair of electrons, thereby increasing the antioxidant capacity of coenzyme Q in biomembranes. In addition, ubisemiquinone, which was earlier shown to be an active oxygen radical source when existing in the anionic form, is removed from equilibrium by the addition of a single electron from DHLA. The high reactivity of DHLA with this potentially deleterious ubisemiquinone species not only prevents the formation of prooxidants, it also keeps ubiquinone in its antioxidant active form.
The functions of the ALA/DHLA system include: quenching of reactive oxygen species, regeneration of exogenous and endogenous antioxidants such as vitamins C and E and glutathione, chelation of metal ions, and reparation of oxidized proteins.
3.4 Enhancement of Glutathione Synthesis
Lipoic acid (thioctic acid) is reported to have beneficial effects in disorders associated with oxidative stress. Evidence shows that lipoic acid induces a substantial increase in cellular reduced glutathione in cultured human Jurkat T cells, human erythrocytes, C6 glial cells, NB41A3 neuroblastoma cells, and peripheral blood lymphocytes. The effect depends on metabolic reduction of lipoic acid to dihydrolipoic acid. Dihydrolipoic acid is released into the culture medium where it reduces cystine; cysteine thus formed is readily taken up by the neutral amino acid transport system and utilized for glutathione synthesis.
3.5 Metal Chelation
ALA, a dithiol compound, is often reduced enzymatically to DHLA. ALA and DHLA have gained interest because of their potential role in free-radical scavenging, metal chelation, and restoring intracellular glutathione (GSH) levels against environmental pollutants such as heavy metals.
Both LA and DHLA can chelate heavy metals. LA is most effective in chelating Cu²⁺, Zn²⁺ and Pb²⁺, but cannot chelate Fe³⁺. DHLA forms complexes with Cu²⁺, Zn²⁺, Pb²⁺, Hg²⁺ (mercury) and Fe³⁺ that are poorly soluble in water. Although DHLA chelates Fe³⁺, it can also reduce Fe³⁺ to Fe²⁺—a pro-oxidant effect it shares with ascorbic acid.
3.6 Protein Redox Modulation and Signaling
LA has been shown to improve glucose and ascorbate handling, increase eNOS activity, activate Phase II detoxification via the transcription factor Nrf2, and lower expression of MMP-9 and VCAM-1 through repression of NF-κB. LA and its reduced form, dihydrolipoic acid, may use their chemical properties as a redox couple to alter protein conformations by forming mixed disulfides.
DHLA protected PC12 cells from metal-induced DNA damage upon co-exposure to metals. Furthermore, ALA and DHLA upregulated the expression of survival-related proteins mTOR (mammalian target of rapamycin), Akt (protein kinase B), and Nrf2 (nuclear factor erythroid 2-related factor 2) in PC12 cells, which were previously downregulated by metal exposure.
3.7 Role in Mitochondrial Energy Metabolism
LA is covalently bound to the ε-amino group of lysine residues and functions as a cofactor for mitochondrial enzymes by catalyzing the oxidative decarboxylation of pyruvate, α-ketoglutarate and branched-chain α-keto acids. DHLA is the reduced species that results from, and is required for, this catalytic cycling. Lipoic acid is transiently reduced to dihydrolipoic acid, and this reduced form is also a substrate for the pyruvate dehydrogenase complex in the oxidative decarboxylation of alpha-keto acids, principally pyruvate.
Lipoic acid is known to occur in α-keto acid dehydrogenases from a variety of organisms. It is normally bound to the ε-amino group of a lysine residue (analogous to biotin) allowing the cofactor to extend out and away from the enzyme surface as a flexible arm.
4. Scientific Evidence by Area of Use
4.1 Diabetic Peripheral Neuropathy
The most extensively studied clinical application for the LA/DHLA system is the treatment of diabetic peripheral neuropathy (DPN). The therapeutic use of ALA has been explored in various clinical scenarios, including cardiovascular diseases and diabetic complications such as DPN. Clinical trials have used different methods of administration (intravenous or oral), different doses (from 200 mg/day to 1,800 mg/day), and different durations of treatment. Recommendations for maintenance therapy indicate a daily oral dose of 600 mg.
Early in-vitro studies indicated that both ALA and its reduced form, dihydrolipoic acid (DHLA), are capable of scavenging ROS, including hydroxyl radicals, hypochlorous acid, and singlet oxygen.
Trials conducted with neuropathic diabetes patients who received 600 mg alpha-lipoic acid demonstrated that treatment reduced pain, paresthesias, and numbness. Oral treatment with alpha-lipoic acid for five weeks improved neuropathic symptoms and deficits in 187 patients with diabetic symmetrical polyneuropathy. An oral dose of 600 mg once daily seems to provide the optimum risk-to-benefit ratio in the SYDNEY 2 trial.
A 2012 meta-analysis (PMC3272801) pooling data from multiple randomized controlled trials found that: the pooled standardized mean difference estimated from all trials revealed a reduction in TSS scores of −2.26 (CI: −3.12 to −1.41; P = 0.00001) in favour of alpha-lipoic acid administration. Subgroup analyses of oral administration (−1.78 CI: −2.45 to −1.10; P = 0.00001) and intravenous administration (−2.81 CI: −4.16 to −1.46; P = 0.0001) confirmed the robustness of the overall result. A significant improvement in the TSS scores was reported in all studies, with an average 50% reduction seen in the TSS with the oral or intravenous administration of at least 600 mg per day.
However, a 2024 Cochrane systematic review reached a more cautious conclusion: alpha-lipoic acid compared to placebo probably has little or no effect on symptoms of diabetic peripheral neuropathy and may have little or no effect on impairment after six months of treatment. The review found three studies that analysed 816 adults with type 1 and type 2 diabetes. This underscores the importance of trial duration, endpoint selection, and methodological quality in interpreting the evidence base; overall, the clinical evidence is mixed, with shorter-term (3-week IV) data being more consistently positive than longer-term oral data.
A general problem with all preclinical and clinical studies is the selection of the optimal dose of ALA, treatment duration, trial outcomes, and the specific metabolism of the antioxidant, which results in somewhat contradictory patient outcomes.
4.2 Oxidative Stress, Cellular Redox Status, and Antioxidant Defense
The most robust body of evidence supporting DHLA's biological importance is biochemical and cell-based. Thioctic (lipoic) acid is used as a therapeutic agent in a variety of diseases in which enhanced free radical peroxidation of membrane phospholipids has been shown to be a characteristic feature. It was suggested that the antioxidant properties of thioctic acid and its reduced form, dihydrolipoic acid, are at least in part responsible for the therapeutic potential.
It is believed that alpha-lipoic acid or its reduced form, dihydrolipoic acid, have many biochemical functions acting as biological antioxidants, as metal chelators, reducers of the oxidized forms of other antioxidant agents such as vitamin C and E, and modulator of the signaling transduction of several pathways.
DHLA homologues with shorter hydrocarbon tails had greater ability to quench superoxide radicals (O₂⁻); no differences among homologues with different chain lengths were found for peroxyl radical scavenging in aqueous solution; and DHLA was the best membrane antioxidant in terms of peroxyl radical scavenging and lipid peroxidation inhibition. This in vitro work indicates DHLA functions as a universal antioxidant, active in both aqueous and lipid compartments of cells.
ALA/DHLA have some important advantages over other antioxidant agents such as vitamin E and C, because they have amphiphilic properties that confer their antioxidant actions in both lipid and aqueous biological environments.
Evidence strength note: The bulk of mechanistic evidence for DHLA's antioxidant actions derives from in vitro and cell culture experiments, with animal model data supporting many findings. Well-designed, adequately-powered human clinical trials specifically examining DHLA (as opposed to the parent compound ALA) are very limited; most clinical literature addresses ALA supplementation, with DHLA understood as an active metabolite.
4.3 Neuroprotection
Excessive production of ROS can overwhelm the endogenous antioxidant defense system, resulting in lipid peroxidation, DNA strand breaks, protein denaturation and cross-linking. The brain is particularly vulnerable to oxidative injury, because it contains high concentrations of readily oxidizable poly-unsaturated fatty acids, has a high rate of oxygen consumption per unit mass, and has only a relatively modest antioxidant defense system.
Pre-treatment of neurons with DHLA (4 hours) provided dose-dependent neuroprotection against a subsequent exposure to H₂O₂. The addition of spin-trapping nitrones to the pre-treatment cocktail enhanced neuroprotection at every dihydrolipoate concentration tested. These results were observed in primary cultures of neurons derived from embryonic rat forebrain and represent in vitro evidence only.
DHLA has been reported as a strong antioxidant and exhibits anti-inflammatory properties in various diseases, though its direct relevance to depression was previously unknown. One study aimed to investigate the preventive effect and potential mechanism of DHLA in LPS-induced sickness behavior in rats. That animal study found that DHLA modulated the Nrf2/HO-1/NLRP3 signaling axis, suggesting a mechanism by which DHLA can suppress neuroinflammation. This evidence is preclinical only.
Both ALA and its reduced form, DHLA, effectively scavenge ROS and promote endogenous antioxidant defenses by regenerating other antioxidants such as vitamins C and E. Preclinical studies demonstrate that ALA crosses the blood-brain barrier and exerts neuroprotection by activating the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway, which upregulates antioxidant enzymes.
Many studies have reported beneficial effects of LA in the rat brain or neuronal cell cultures, using different molecular markers of oxidative stress, such as reduction in the levels of lipid peroxides and protein carbonyls, recycling endogenous antioxidants such as vitamin C and E, and increasing glutathione levels.
One clinical study aimed to investigate the effects of ALA on oxidative stress and brain injury in patients under sevoflurane anesthesia, hypothesizing that ALA would mitigate ROS-mediated DNA damage, restore redox homeostasis, and reduce biomarkers of brain damage. The study included patients who underwent liver resection. Postoperatively, both S100β and UCH-L1 levels were significantly lower in the ALA group compared to the placebo group (S100β, P = 0.02; UCH-L1, P = 0.03). This provides limited but direct human evidence for ALA-mediated (and thus likely DHLA-mediated) neuroprotection in an operative setting.
Evidence strength note: Evidence for neuroprotection is predominantly preclinical (in vitro and animal models). Human clinical data in neurodegenerative diseases is sparse and mostly derived from trials of the parent compound ALA.
4.4 Heavy Metal Detoxification
Alpha-lipoic acid (ALA), a disulfide, and its metabolite dihydrolipoic acid (DHLA), a dithiol, have been shown to have chelation properties when used in an appropriate manner.
ALA and its reduced form DHLA are endogenous dithiol compounds with significant antioxidant properties, both of which have the potential to detoxify cells. In cell studies, ALA (250 μM) and DHLA (50 μM) were applied to reduce metal (As, Cd, and Pb)-induced toxicity in PC12 and Caco-2 cells. Both significantly decreased Cd (5 μM)-, As (5 μM)-, and Pb (5 μM)-induced cell death. Subsequently, both ALA and DHLA restored cell membrane integrity and intracellular glutathione (GSH) levels. In addition, DHLA protected PC12 cells from metal-induced DNA damage upon co-exposure to metals.
ALA and DHLA can react with oxidizing molecules to strengthen the primary antioxidant defense system during cell injury. The compound ALA is suggested for heavy metal detoxification, in particular for supporting the mercury (Hg) detoxifying process.
Evidence strength note: Evidence for heavy metal chelation by DHLA is predominantly in vitro and animal-based. Controlled human clinical trials specifically demonstrating clinically meaningful metal detoxification via ALA/DHLA supplementation are lacking, and this area is considered preliminary.
4.5 Cardiovascular Health
Dihydrolipoic acid is reported for its blood lipid modulating characteristics, protection against LDL oxidation, and modulation of hypertension, indicating that α-lipoic acid might be a possible protective agent against cardiovascular diseases.
In vitro and in vivo studies demonstrated ALA's protective role in lipotoxic cardiomyopathy and in maintaining cardiovascular function under hypoxic conditions. While ALA generally exhibits cardioprotective effects, primarily due to its antioxidant properties, it may provoke adverse cardiovascular effects under certain metabolic conditions, particularly in diabetic settings where oxidative stress is poorly regulated.
ALA and its active reduced counterpart, dihydrolipoic acid (DHLA), have been shown to combat oxidative stress by quenching a variety of reactive oxygen species (ROS). Because this molecule is soluble in both aqueous and lipid portions of the cell, its biological functions are not limited solely to one environment.
Evidence strength note: Cardiovascular evidence for the ALA/DHLA system is primarily derived from preclinical models and mechanistic studies. Human clinical data are limited and do not yet establish DHLA or ALA as established cardiovascular therapies.
4.6 Metabolic Effects: Insulin Sensitivity and Glucose Metabolism
ALA activates the insulin receptor by binding to it extracellularly and can also traverse the cell membrane to activate AMPK, which enhances GLUT4 expression and glucose uptake. This leads to increased glycolysis and initiates the Krebs cycle via interaction with pyruvate dehydrogenase.
Studies examining weight loss have used doses of ALA ranging from 1,000 mg to 1,800 mg for up to 20 weeks in obese patients with or without glucose intolerance and have shown a weight loss of around 3 kg, corresponding to approximately 3% of body weight.
One study did not show any advantage of ALA supplementation for two weeks over lipid-induced insulin resistance in obese or overweight subjects. However, an intravenous treatment with 600 mg of ALA for two weeks in obese patients with glucose intolerance resulted in improvement of insulin resistance.
Evidence strength note: Metabolic effects in humans are mixed and dose-dependent. Intravenous administration shows more consistent results than oral administration, partly due to bioavailability differences. More data specifically on DHLA-mediated metabolic effects are needed before firm conclusions can be drawn.
4.7 Anti-Inflammatory Effects and NF-κB Pathway Modulation
LA has an influence on the second messenger nuclear factor κB (NF-κB) and attenuates the release of free radicals and cytotoxic cytokines. As the active reduced metabolite of ALA, DHLA is considered to contribute significantly to these effects.
Treatment with dihydrolipoic acid-coated gold nanoclusters (DHLA-Au NCs) has been shown to inhibit the activation of JNK and its downstream target c-Jun, subsequently suppressing AP-1-mediated TNF-α expression, thereby contributing to the attenuation of cellular inflammation and senescence. This evidence is preclinical in vitro data.
As an antioxidant, LA and its reduced form, dihydrolipoic acid (DHLA), have been shown to protect against peroxynitrite-induced tissue damage by acting as scavengers of reactive oxygen and nitrogen species.
4.8 Prooxidant Properties: A Documented Caveat
Critically, DHLA is not exclusively antioxidant in its actions. DHLA accelerated iron-dependent hydroxyl radical generation and lipid peroxidation, probably by reducing Fe³⁺ to Fe²⁺. LA inhibited this pro-oxidant action of DHLA. This reduction of ferric iron to the more reactive ferrous form is a documented pro-oxidant mechanism by which DHLA, under specific redox conditions, can paradoxically amplify rather than suppress oxidative damage. This nuance underscores the importance of the iron-chelating capacity of the LA/DHLA system as a whole and the context-dependence of DHLA's antioxidant versus pro-oxidant behavior.
Dihydrolipoic acid scavenges various ROS and RNS and chelates heavy metals; however, it is present in much lower concentrations in tissues compared to GSH and ascorbate. Consequently, the importance of its function as an antioxidant in vivo is considered open to question by some researchers.
5. Body Systems and Health Areas of Association
- Peripheral Nervous System: The role of oxidative stress in nerve damage has been extensively studied in experimental and clinical diabetes. Alpha-lipoic acid has been shown to improve motor-nerve conduction velocity in experimental diabetic neuropathy and to protect peripheral nerves from ischemia in rats.
- Central Nervous System: DHLA has documented neuroprotective effects in cell and animal models of oxidative injury, ischemia-reperfusion, and neuroinflammation. The brain is particularly vulnerable to oxidative injury, because it contains high concentrations of readily oxidizable poly-unsaturated fatty acids, has a high rate of oxygen consumption per unit mass, and has only a relatively modest antioxidant defense system.
- Mitochondria and Energy Metabolism: LA is found naturally in mitochondria where it is bound to the subunit E2 and where it acts as the coenzyme for pyruvate dehydrogenase and α-ketoglutarate dehydrogenase. DHLA is the essential reduced form generated during this catalytic cycling.
- Endocrine System / Glucose Homeostasis: ALA/DHLA have documented activity at the insulin receptor and AMPK pathway level, influencing glucose uptake and insulin sensitivity.
- Cardiovascular System: Protection against LDL oxidation, modulation of endothelial nitric oxide synthase (eNOS), and downregulation of inflammatory adhesion molecules (VCAM-1) have been demonstrated in experimental models.
- Immune and Inflammatory Pathways: Modulation of NF-κB and downstream cytokine production has been demonstrated in cell studies. DHLA is a reduced form of ALA that can decrease oxidative stress and act as a strong antioxidant, and DHLA also possesses anti-inflammatory properties.
- Skin: Research has cited DHLA as inhibiting skin tumor promotion through anti-inflammatory and anti-oxidative mechanisms (Ho et al., 2007, Biochemical Pharmacology 73:1786–1795). Topical ALA formulations, whose in situ reduction to DHLA within skin cells is presumed, are used in cosmeceutical applications for their antioxidant effects.
- Detoxification Pathways: The dithiol structure of DHLA enables chelation of multiple heavy metals including Hg²⁺, Pb²⁺, Cd²⁺, As³⁺, and Cu²⁺, with predominantly cell and animal model evidence.
6. Dosage Forms and Reported Dosages
DHLA itself is not currently widely available as a standalone dietary supplement due to its chemical instability; the overwhelming majority of clinical and supplementation data concerns ALA, the precursor that is reduced in vivo to DHLA. The following dosages are those reported in peer-reviewed clinical studies for ALA:
- Clinical trials for diabetic peripheral neuropathy have used different methods of administration (intravenous or oral), different doses (from 200 mg/day to 1,800 mg/day), and different durations of treatment. Recommendations for maintenance therapy indicate a daily oral dose of 600 mg.
- An oral dose of 600 mg once daily appears to provide the optimum risk-to-benefit ratio (from the SYDNEY 2 trial). Adverse effects (mainly nausea) with the 1,200 mg dose daily occurred in 21% of patients, somewhat higher than that observed in the ALADIN I (15%) and ALADIN II study (7%) with the same dose.
- Studies examining weight outcomes have used doses of ALA ranging from 1,000 mg to 1,800 mg for up to 20 weeks in obese patients.
- An intravenous treatment with 600 mg of ALA for two weeks in obese patients with glucose intolerance has been used in metabolic studies.
- When given intravenously at a dosage of 600 mg/day over a period of 3 weeks, alpha-lipoic acid leads to a significant and clinically relevant reduction in neuropathic pain.
- In cell studies examining DHLA's direct effects on metal-induced cytotoxicity, concentrations of DHLA (50 μM) and ALA (250 μM) have been used in vitro.
Maximum plasma levels of LA have been observed between 10–60 minutes post oral administration, with a plasma half-life of 30 minutes. When supplemented orally as thioctic acid (a racemic mixture of R-LA and S-LA), maximum plasma concentrations of R-LA were observed to be 40–50% higher than S-LA. Maximum bioavailability of oral LA has been observed to be 38% as R-LA and 28% as S-LA.
Data suggests that ALA has a short half-life and bioavailability (about 30%) triggered by its hepatic degradation, reduced solubility, as well as instability in the stomach. However, the use of various innovative formulations has greatly improved ALA bioavailability. The R enantiomer of ALA shows better pharmacokinetic parameters, including increased bioavailability, compared to its S enantiomer.
7. Safety Considerations and Interactions
7.1 General Safety Profile
ALA has proven to be safe at the recommended therapeutic dose of 600 mg/day. LA and its reduced form—dihydrolipoic acid (DHLA)—meet all the criteria for an ideal antioxidant because they can easily quench radicals, can chelate metals, have an amphiphilic character, and they do not exhibit any serious side effects at standard doses. However, several specific and pharmacologically relevant adverse reactions have been documented.
7.2 Gastrointestinal and Dermatological Adverse Effects
In an analysis of spontaneous adverse reaction reports, skin disorders (44.9%) and gastrointestinal disorders (10.8%) were the most frequently represented adverse reactions to ALA-containing dietary supplements. In 70% of cases, events occurred within 30 days of ALA use. Of 116 total reports analyzed, 45 were serious (38.8%), with insulin autoimmune syndrome being the most frequently reported serious event (N = 10).
The most common adverse effects of lipoic acid supplementation include urticaria and mild gastric upset; however, the possibility of insulin autoimmune syndrome (characterized by spontaneous hypoglycemia) exists.
7.3 Insulin Autoimmune Syndrome (Hirata's Disease)
A clinically important and non-trivial safety concern associated with the ALA/DHLA system is the risk of inducing insulin autoimmune syndrome (IAS), also called Hirata's disease. ALA can induce insulin autoimmune syndrome (IAS; also known as Hirata's disease), characterized by hypoglycemia, high concentrations of immunoreactive insulin, and high titers of antibodies to endogenous insulin, even without prior exposure to exogenously administered insulin.
ALA may alter insulin by cleaving disulfide bonds, which exposes fragments to the immune system and results in the production of insulin autoantibodies (IAA), contributing to IAS. IAA is a type of IgG antibody with low affinity and high capacity, causing postprandial and nocturnal hypoglycemia in IAS patients.
Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion on the relationship between alpha-lipoic acid (ALA) and the risk of insulin autoimmune syndrome (IAS). The Panel was also asked to advise on the dose below which ALA added to foods is not expected to cause IAS. Published scientific evidence was retrieved through comprehensive literature searches, particularly 49 case reports in which IAS developed following ALA consumption.
7.4 Interaction with Antidiabetic Medications
Because lipoic acid supplementation may improve insulin-mediated glucose utilization, there is a potential risk of hypoglycemia in diabetic patients using insulin or oral anti-diabetic agents. Consequently, blood glucose concentrations should be monitored closely when lipoic acid supplementation is added to diabetes treatment regimens.
7.5 Pro-oxidant Risk Under Specific Conditions
DHLA can accelerate iron-dependent hydroxyl radical generation and lipid peroxidation, probably by reducing Fe³⁺ to Fe²⁺, a pro-oxidant effect. This means that DHLA's safety and efficacy profile may differ depending on the tissue iron status of an individual. In situations of elevated free iron (e.g., hemochromatosis or iron overload), supplementation with compounds generating DHLA warrants caution.
7.6 Thyroid Interactions
In addition to the above, research and regulatory signals have highlighted a potential interaction of ALA with thyroid hormone metabolism. Some in vitro data suggest that high-dose ALA may inhibit iodothyronine deiodinase enzymes; however, the clinical significance of this interaction at supplemental doses has not been firmly established in human studies.
7.7 Serious Immune Reactions
Immune-mediated events (IMEs) were recorded in 20 cases from the Italian Phytovigilance System report, including four drug-mediated events: three cases of angioedema and one anaphylactic shock. A similar distribution of serious adverse events emerged from the 5,641 reports in the WHO-VigiBase.
The remarkable reporting of unpredictable skin, immune and hepatic adverse reactions, coupled with seriousness, strong causality and early onset, calls for careful risk-benefit assessment of ALA-containing products by regulators; awareness and monitoring by clinicians; and continuous vigilance of their safety profile through spontaneous reporting systems.
8. Summary of Evidence Strength
The scientific evidence for DHLA and the LA/DHLA redox system varies considerably by area of application:
- Biochemical/mechanistic role in mitochondrial energy metabolism: Established and uncontested — DHLA is an obligatory participant in the catalytic cycling of mitochondrial dehydrogenase complexes.
- Antioxidant properties (in vitro and animal models): Strong — Direct free radical scavenging, antioxidant regeneration, and metal chelation are well-documented in cell and animal systems.
- Diabetic peripheral neuropathy (clinical): Mixed — Positive short-term results with IV administration; evidence for long-term oral treatment is conflicting, with a 2024 Cochrane review finding little or no effect on symptoms over six months.
- Neuroprotection (clinical): Preliminary — Encouraging preclinical data; limited human evidence.
- Heavy metal chelation (clinical): Preliminary/insufficient human evidence — Supported by cell studies and animal models; controlled human trials are lacking.
- Cardiovascular and metabolic effects (clinical): Mixed and preliminary — Mechanistically plausible; clinical evidence is inconsistent and limited.
- Anti-inflammatory and Nrf2 pathway modulation: Preclinical — Well-established in cell-based models; clinical translation remains under investigation.
References
Go back